Top Wall Street analysts have released new ratings on several companies, including Adial Pharmaceuticals, Achieve Life Sciences, and Rockwell Medical, with Buy recommendations. Read on for a breakdown of these ratings and their potential impact.
Results for: Buy Rating
Top Wall Street analysts have weighed in on a number of promising companies, issuing Buy and Outperform ratings for Alumis Inc., Enliven Therapeutics, Intensity Therapeutics, and Terns Pharmaceuticals. This article delves into the specific price targets set by these analysts and offers insights into the potential upside these stocks hold.
Top Wall Street analysts have initiated coverage on four promising companies, issuing buy ratings and price targets that suggest significant upside potential. Learn about the analysts’ rationale for these bullish calls and how these companies are positioned for growth.
Top Wall Street analysts have initiated coverage on several companies with Buy ratings, signaling potential investment opportunities. RxSight, Six Flags Entertainment, Evergy, CRH plc, and Quince Therapeutics are among the companies receiving positive outlooks from analysts, potentially attracting investor interest.
Truist Securities analyst Bertrand Donnes initiated coverage on BKV Corporation (BKV) with a Buy rating and a price target of $24, highlighting the company’s unique ‘closed-loop’ system and strong growth potential across its three segments. The analyst expects BKV to deliver on all three segments by 2025, with the company well-positioned to consolidate Barnett upstream assets, expand its Power JV into data center demand, and pursue larger CCUS projects.
Top Wall Street analysts have initiated coverage on five companies with Buy ratings, setting price targets that suggest potential upside. Find out which companies are getting the bullish attention and what the analysts are saying about their prospects.
Goldman Sachs analyst Bonnie Herzog maintains a Buy rating on Kimberly-Clark Corporation (KMB) stock, citing the company’s strong growth potential fueled by productivity initiatives and a favorable market environment. Despite missing revenue estimates, the analyst expects Kimberly-Clark to see margin expansion and healthy EPS growth, driven by a potential for robust gross margin expansion. Herzog believes the market undervalues Kimberly-Clark’s growth potential, offering a compelling entry point for investors.
Truist Securities has initiated coverage on Guardian Pharmacy Services (GRDN) with a ‘Buy’ rating and a price target of $22. The firm sees a sizable market opportunity for the company, which operates long-term care pharmacies, citing strong industry trends driven by the aging population and an increase in residents at assisted living facilities. Truist believes Guardian’s differentiated scale, suite of capabilities, and strategic market targeting make it well-positioned for growth.
DA Davidson analyst Manuel Navas initiated coverage on Burke & Herbert Financial Services (BHRB) with a ‘Buy’ rating and a price target of $76. Navas sees strong earnings potential and an attractive valuation for the company, driven by robust loan growth, repricing opportunities, and a favorable market position.
Needham analyst Kyle Peterson initiated coverage on Axos Financial with a ‘Buy’ rating and a price target of $82.00, highlighting the company’s digital-first strategy, strong profitability, and potential for growth. Peterson believes Axos Financial’s unique approach and corporate culture position it for continued success in the banking industry.